Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic–pituitary–adrenal (HPA) axis suppression, has limited their use.
Objective:
This article reviews the topical steroid prednicarbate through its mechanism of action, clinical efficacy, and adverse events profile.
Methods:
Published literature containing the word “prednicarbate” was examined and summarized.
Results:
Prednicarbate is a nonhalogenated, double-ester derivative of prednisolone that has been used in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic dermatitis. It has a favorable benefit–risk ratio, low skin atrophy potential, and high anti-inflammatory action.
Conclusion:
These characteristics make prednicarbate an ideal alternative agent for children, elderly patients, and those who require long-term intermittent treatment.
Get full access to this article
View all access options for this article.
References
1.
TrozakDJ. Topical corticosteroid therapy in psoriasis vulgaris: Update and new strategies. Cutis1999; 64:315–318.
2.
DegreefHDooms-GoossensA. The new corticosteroids: Are they effective and safe?Dermatol Clin1993; 11:155–160.
3.
Dermatop®, Emollient Cream (prednicarbate emollient cream 0.1%) U.S. prescribing information. Dermik Laboratories, Berwyn, PA, May 2003.
4.
KerscherMJKortingHC. Topical glucocorticoids of the non-fluorinated double-ester type: Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol1992; 72:214–216.
5.
KortingHCHulsebusEKerscherM. Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts. Br J Dermatol1995; 133:54–59.
6.
LangeKKleuserBGyslerA. Cutaneous inflammation and proliferation in vitro differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol2000; 13:93–103.
7.
HeinRMauchCHatamochiA. Influence of corticosteroids on chemotactic response and collagen metabolism of human skin fibroblasts. Biochem Pharmacol1988; 37:2723–2729.
8.
LangeKGyslerABaderM. Prednicarbate versus conventional topical glucocorticoids: Pharmacodynamic characterization in vitro. Pharm Res1997; 12:1744–1749.
9.
GyslerAKleuserBSipplW. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res1999; 16:1386–1391.
10.
HanifinJAbramsBBCherillRJ. Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a nonhalogenated prednisolone derivative. J Geriatr Dermatol1994; 24:119–127.
11.
Schafer-KortingMKortingHCKerscherMJ. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther1993; 54:448–456.
12.
MoshangT. Prednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitis. Cutis2001; 68:63–69.
13.
SchmittEWHohlerTWormsG. Long-term observation of the therapy with prednicarbate [in German]. Z Hautkr1989; 64 (Supp. 1): 56–60. In: SpencerCMWagstaffAJ. Prednicarbate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs1998; 9: 61–86.
14.
SchulzH. Investigation of the efficacy of halogen-free prednicarbate as compared to a fluorinated standard corticoid—an intra-individual half-sided double blind study [in German]. Z Hautkr1989; 64(Suppl. 1): 40–46. In: SpencerCMWagstaffAJ. Prednicarbate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs1998; 9: 61–86.
15.
UlrichRAndresenI. Double-blind comparative trial involving 0.5% halomethasone (Sicorten®) cream versus 0.25% prednicarbate cream in patients with acute episodes of atopic dermatitis [in German]. Fortschr Med1991; 109: 741–744. In: SpencerCMWagstaffAJ. Prednicarbate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs1998; 9: 61–86.
16.
NoltingSGlowaniaH-JGranderK. Therapie des atopischen ekzems im kindesalter. Ergebnisse einer kontrollierten studie mit den topischen kortikosteroids-zubereitungen momtaso und prednikarbat. Kinderarzt1991; 22: 1691–1694. In: SpencerCMWagstaffAJ. Prednicarbate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs1998; 9: 61–86.
17.
HerzX. An open study with HOE 777 0.25% emollient cream in children aged 1 to 12 years with contact dermatitis, atopic dermatitis, seborrheic eczema or psoriasis. Barcelona, Spain: Laboratories Novag (Grupo Ferrer), 1997. In: SpencerCMWagstaffAJ. Prednicarbate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs1998; 9: 61–86.
18.
HerzX. An open study with HOE 777 0.25% emollient cream in children up to 1 year with seborrheic eczema. Barcelona, Spain: Laboratories Novag (Grupo Ferrer), 1997. In: SpencerCMWagstaffAJ. Prednicarbate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs1998; 9: 61–86.
19.
CornellRCCherillRJAbramsBB. Safety of prednicarbate emollient cream 0.1% and ointment 0.1%, nonhalogenated, mid-potency topical steroid formulations. J Geriatr Dermatol1994; 2:57–65.
20.
MaturaMGoosensA. Contact allergy to corticosteroids. Allergy2000; 55:698–704.
21.
CoopmanSDegreefHDooms-GoosensA. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol1989; 121:27–34.
22.
Dermatop® Emollient Cream (prednicarbate emollient cream) 0.1% and Dermatop® E Emollient Ointment (prednicarbate ointment) 0.1% U.S. package insert. Dermik Laboratories Berwyn, PA, June 2002.
23.
Dermatop® Oinment (prednicarbate Oinment 0.1%) and Dermatop® Emollient Cream (prednicarbate emollient cream 0.1%) Canadian package insert. Dermik Laboratories Canada, Inc., Mississauga, ON, Canada, November 15, 2000.
